Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temanogrel - Pfizer

Drug Profile

Temanogrel - Pfizer

Alternative Names: APD-791; Temanogrel hydrochloride

Latest Information Update: 20 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Ildong Pharmaceutical; Pfizer
  • Class Anti-ischaemics; Antithrombotics; Benzamides; Cardiovascular therapies; Morpholines; Phenyl ethers; Pyrazoles; Small molecules; Vascular disorder therapies
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial ischaemia; Raynaud's disease
  • Suspended Arterial thrombosis
  • Discontinued Acute coronary syndromes

Most Recent Events

  • 20 Sep 2022 Arena Pharmaceuticals terminates phase II trial in Raynaud's disease (In adults, In the elderly) in the UK and USA (PO) due to a business decision (NCT04915950)
  • 23 Aug 2022 Arena Pharmaceuticals terminates a Phase-II clinical trial in Myocardial ischaemia (In the elderly, In adults) in Australia, Netherlands, USA, United Kingdom and Sweden(IV), due to business decision (EudraCT2020-000238-16)
  • 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top